Anti-CS1 × Anti-CD3 Bispecific Antibody (BiAb)-Armed Anti-CD3 Activated T Cells (CS1-BATs) Kill CS1(+) Myeloma Cells and Release Type-1 Cytokines

Background: Multiple myeloma (MM) remains incurable despite significant advances in chemotherapy, targeted therapies, and immunotherapy. Bispecific antibody (BiAb)-armed activated T cells (BATs) have been developed for targeting and treatment of solid and hematologic malignancies. BATs are serial ki...

Descripción completa

Detalles Bibliográficos
Autores principales: Lum, Lawrence G., Thakur, Archana, Elhakiem, Abdalla, Alameer, Lena, Dinning, Emily, Huang, Manley
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7214537/
https://www.ncbi.nlm.nih.gov/pubmed/32432032
http://dx.doi.org/10.3389/fonc.2020.00544

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7214537/
https://www.ncbi.nlm.nih.gov/pubmed/32432032
http://dx.doi.org/10.3389/fonc.2020.00544

Ejemplares similares